Introduction
Dilated cardiomyopathy (DCM) is one of the most common causes of heart failure without an ischemic etiology and the most common reason for heart transplantation. In many cases, the underlying causes of DCM are unknown or "idiopathic" and may affect individuals across all ages. There has been a long-standing interest in exploring the contribution of autoimmunity toward the pathogenesis of DCM. This is based on the presence of anticardiac autoantibodies (AAbs) in a subset of patients with DCM. It has been postulated that myocardial tissue damage may lead to the release of intracellular proteins that can serve as "self-antigens" in order to provoke humoral responses leading to the generation of AAbs. On the other hand, dysregulated humoral immunity itself can serve as the primary driver of AAb production, directly contributing to progressive myocyte damage as observed in some systemic autoimmune disorders associated with cardiac complications (e.g., systemic lupus erythematosus).
Over the past decades, researchers have investigated the direct physiological role of AAbs via basic in vitro or in vivo experiments, as well as via modulation of their effects by removal or neutralization. In this review article, we critically examine the contemporary understanding of specific AAbs that have been mechanistically linked to the pathogenesis of DCM with emphasis on the discussion of how quantitative AAb measurements may lead to potential therapeutic implications.
Dilated Cardiomyopathy: a Possible Autoimmune Origin
Several cardiac AAbs have been consistently reported to be present in sera from patients with DCM [1] [2] [3] . However, such associations do not necessarily establish causality, especially when the acuity, time course, and localization of autoimmune responses are largely unknown. Earlier research focus was based upon establishing the association between introduction of AAbs and induction of DCM phenotypes. Indeed, immunization with noncardiac peptides such as β 1 -adrenergic receptor (β 1 AR) second extracellular loop [4, 5] or muscarinic M 2 acetylcholine receptor (M 2 R) [6, 7] , as well as cardiacspecific peptides such as myosin [8] or troponin I [9] , can directly lead to the generation of AAbs and myocarditis-or DCM-like phenotype in experimental animals. These findings support the development of AAbs upon exposure to "selfantigens," thereby establishing the first step for specific AAbs as contributors in the development of DCM. Clinical and translational research studies regarding these specific AAbs are illustrated in Table 1 .
Antimyosin Autoantibody
The antimyosin AAb has long been studied for its causal roles in the pathology of myocarditis or DCM. In 1987, immunization with cardiac myosin was found to induce antimyosin AAbs and myocarditis in certain strains of mice [8] . However, since transfer of serum with high titer antimyosin AAbs from C.B-17 mice to severe combined immune deficiency (SCID) mice failed to cause myocarditis [11] , the pathogenic role of antimyosin AAbs was questioned by some researchers. It has been proposed that myosin or a similar protein was present in the extracellular matrix of susceptible mouse strains [12] . And the pathogenic effects of antimyosin AAbs were mediated at least partly by reacting with β-adrenergic receptor and activating downstream protein kinase A pathway [10] . In humans, antimyosin AAbs are detected in 20-30 % of patients with DCM and 4-30 % in those with ischemic cardiomyopathy (ICM) [13, 43] . However, the clinical findings regarding the significance of antimyosin AAbs are inconsistent. One study showed that persistence of antimyosin AAb was associated with milder symptoms at presentation and stable disease [13] , whereas antimyosin AAbs were also shown to associate with deterioration of left ventricular function in patients with biopsyproven chronic myocarditis [14] .
Autoantibody Against β 1 -Adrenergic Receptor (β 1 AR-AAb) Detectable circulating AAbs against β 1 AR have been observed in approximately 30-40 % of patients with chronic heart failure due to DCM [4, [44] [45] [46] [47] . β 1 AR-AAb shows agonist-like effects [15] [16] [17] [18] , inducing receptor uncoupling [4, 19, 20] , myocyte apoptosis [21] , sustained calcium influx resulting in electric instability of the heart [22] , and persistent myocardial damage [5] . These effects were abolished by β-blockers in vitro [18, 26] and in vivo [4] . There have also been prior reports demonstrating the association between detectable β 1 AR-AAb and increased mortality [26] as well as the occurrence of fatal ventricular arrhythmias and sudden death [4, 23] in patients with DCM. However, a majority of the subjects in these association studies were not receiving antiadrenergic therapy at the time. Interestingly, more favorable recovery of cardiac performance in response to β-blocker therapy was observed in β 1 AR-AAb-positive patients compared to AAb autoantibody, DCM dilated cardiomyopathy,
2 R muscarinic M 2 acetylcholine receptor, Af atrial fibrillation, LVEF left ventricular ejection fraction β 1 AR-AAb-negative patients [28] . These findings are consistent with the hypothesis that heightened adrenergic drive associated with β 1 AR-AAb generation in DCM can lead to adverse cardiac consequences. Besides antiadrenergic therapy, studies are currently ongoing to determine if an aptamer for neutralizing β 1 AR-AAbs may curtail disease progression and perhaps even facilitate recovery [30] .
It is important to note that not all of the detectable β 1 ARAAbs uniformly exert their adverse physiological effects across the spectrum of clinical conditions. While β 1 ARAAbs were also detectable in patients with valvular or hypertensive heart disease (or even in some healthy subjects), AAbs in these non-DCM individuals were functionally inactive [24, 25] . Furthermore, the presence of β 1 AR-AAb was consistently associated with increased mortality risk largely in DCM and not in ischemic cardiomyopathy [26] . Evidence also suggests that some β 1 AR-AAbs can be generated, at least partly, by cardiac loading or damage. In an analysis of weaned DCM patients who tested positive for β 1 AR-AAb prior to implantation of left ventricular assist device (LVAD), β 1 AR-AAb disappeared after 3 to 31 weeks following LV unloading by LVAD support in 33 of 34 patients [48] . The potential mechanism of these inconsistencies has not yet been elucidated, and further studies are needed.
Autoantibody Against Muscarinic M 2 Acetylcholine Receptor
Circulating AAbs against the second extracellular loop of M 2 R (M 2 R-AAb) have been detected in a large number of cardiovascular diseases such as DCM and chronic Chagas' disease [32] [33] [34] [35] 49] . M 2 R-AAbs extracted from DCM patients induced a significant decrease in Ca 2+ currents [35] , negative chronotropic effect in vitro [33] , and supraventricular arrhythmia ex vivo [34] which were blocked by M 2 antagonist [34, 35] or a synthetic peptide derived from the second extracellular loop of M 2 R [34] . M 2 R-AAbs were also detected along with the induction of DCM-like morphology in the heart of mice receiving adoptive transfer of splenocytes from M 2 R null mice immunized with synthetic M 2 R peptide [50] . In addition, AAbs from these mice induced a significant decrease in Ca 2+ currents in ventricular cardiomyocytes, which was blocked by M 2 R antagonists or synthetic M 2 R peptides [50] . Clinically, the presence of M 2 R-AAbs was strongly and independently associated with the comorbidity of atrial fibrillation [34] and may serve as an independent predictor for the recurrence of atrial fibrillation after catheter ablation [36] .
Autoantibody Against Troponin I
Monoclonal antibodies against cardiac troponin I (cTnI) induce chamber dilatation and contractile dysfunction of hearts of wild-type mice [9] . Interestingly, the immunization of cTnI, but not cardiac troponin T, induced severe autoimmune inflammation in the mouse myocardium [37] . Monoclonal cTnI-AAbs extracted from mice following immunization with recombinant cTnI are able to increase the voltage-dependent Ltype calcium current in cardiomyocytes of wild-type mice [9] .
Despite promising data regarding the effects of cTnIAAbs in animal models, the pathogenic role of cTnIAAbs in humans and their possible involvement in the pathogenesis of DCM remain controversial. Although the cTnI-AAbs were reported to be detected in DCM and ICM patients [39, 51] , IgG preparations reactive toward cTnI did not exhibit measurable effects on Ca 2+ transients in cultured neonatal rat ventricular cardiomyocytes, nor did they bind the respective cells by direct immunofluorescence [51] . When examining cellular autoimmune responses from peripheral blood mononuclear cells, there were no significant differences between DCM patients with versus without detectable cTnI-AAb levels [52] . Furthermore, in the analysis of 95 patients with DCM, circulating cTnI-AAbs were not associated with patients' clinical status or outcome, while the presence of cTnI was associated with worse cardiac function, morphology, and worse clinical outcome [38] . In contrast, another study showed that cTnI-AAb-positive patients had significantly higher left ventricular ejection fraction and more favorable outcomes than negative patients with DCM, but not ICM [39] .
Data from Immunoadsorption Studies
Like other autoimmune disorders, the removal of pathogenic AAbs by immunoadsorption (IA) therapy can be considered as a therapeutic option for DCM patients. Clinical studies have consistently demonstrated that nonspecific IA can lead to improved hemodynamics and cardiac function and better survival and quality of life in DCM patients [53] [54] [55] [56] [57] [58] [59] [60] (Table 2) . Specifically, IA using the column specific for β 1 AR-AAbs was effective in alleviating the cardiac dysfunction in an observational series of patients with DCM [31, 62] . However, many of these studies are small in sample size and few have blinding or control group comparisons. Moreover, it is also important to point out that nonspecific IA was effective in both patients with β 1 AR-AAbs and those without [29] . These findings suggest the possibility that the causal mechanism in the pathology of DCM cannot be explained solely by β 1 AR-AAbs and that other immune or nonimmune factors may influence the effectiveness of IA in this population.
The potential contribution of cTnI-AAbs is less certain. In a small study, the presence of cTnI-AAbs was not associated with the effect of IA therapy which removes such AAbs. Despite being statistically insignificant, the study even showed a weaker effect of IA on the absolute change of LVEF after 6 months in cTnI-AAb-positive patients [40] .
"Cardiodepressant Autoantibody"
Some groups have shown that IgG antibodies purified from patients with DCM may induce a negative inotropic effect or reduction of calcium transient in adult rat cardiomyocytes [63, 64•] or chick embryo ex vivo systems [65, 66•] . Often referred to as the "cardiodepressant" AAb, the epitope(s) of such AAbs have not been identified. Interestingly, patients with cardiodepressant AAbs demonstrated an acute increase in cardiac index and improvement in left ventricular ejection fraction following IA therapy, while those without such AAbs did not show significant changes [64•, 66•] . Nevertheless, the cardiodepressant effects of these AAbs are unlikely to be induced by either the F(ab′) 2 or Fc fragments alone. Reconstitution of the Fc part by incubation of cardiomyocytes with DCM-F(ab′) 2 fragments followed by goat-anti-human-F(ab′)-IgG again induced reduction of cell shortening and of calcium transients [67•] . Taken together, these findings suggest that AAbs require Fc fragment binding to Fc receptor as well as F(ab′) 2 fragments binding to the epitope peptide in order to exert its pathological effect, and hence, the effects of the AAb vary depending on the structure of the Fc fragment.
The Significance of IgG3 Subclass AAbs
IgG has four subclasses and they differ from one another both immunologically and functionally. Antibodies capable of triggering effector functions and the most likely to be involved in immunoregulatory activities are IgG3 and IgG1. Complement activation through binding of C1q is most effective with IgG3 [68] . Affinity-purified IgG fractions positive for IgG3 antimyosin AAb significantly inhibited the contraction of cardiomyocytes to a greater extent than those with non-IgG3 AAb in vitro [69] . In 1999, Warraich et al. reported that antimyosin AAbs belonging to IgG3 subclass were selectively raised in patients with DCM compared with HF patients of an ischemic etiology [70] . Indices of hemodynamic dysfunction also significantly correlated with antimyosin AAb titer belonging to IgG3, but not total IgG in patients with DCM [71] . AAbs against some other cardiac components belonging to the IgG3 subclass were also detected in patients with DCM, and their presence was an independent predictor of the presence of cardiodepressant AAb [72] . The importance of IgG3 AAbs was supported when cardiac function was improved IA immunoadsorption, IV/IG intravenous immunoglobulin administration, LVEF left ventricular ejection fraction, β 1 AR-AAb autoantibody against β1-adrenergic receptor, CI cardiac index, QOL quality of life with IA via anti-human IgG columns (high affinity for all IgG subclasses) compared to using protein A (high affinity for IgG1, 2, and 4, but low affinity for IgG3) [73] . Column eluent from an anti-IgG column, but not from a protein A column, exerted cardiodepressant effects on rat cardiomyocytes, whereas such cardiodepressant effects were abolished after removal of IgG3 subclass from eluent of an anti-IgG column [61] . Furthermore, IA using a protein A column with a modified protocol to effectively eliminate IgG3 subclass demonstrated better hemodynamic improvement in patients with DCM [74•] . Previously, we performed an IA study for patients with refractory DCM by utilizing a tryptophan column. IA therapy removed IgG3 efficiently and to a greater extent than the other subclasses [60] . Left ventricular ejection fraction significantly increased after IA, and such improvement in cardiac function correlated with the AAb titer belonging to IgG3 subclass more than total IgG, which also suggested that the removal of IgG3-AAb is important to maximize the effect of IA for the patients with DCM [62] . Therefore, AAb belonging to the IgG3 subclass may play a pivotal role in the onset and progression of cardiac dysfunction in new-onset DCM and the therapeutic efficacy of IA. From these findings, anticardiac AAbs belonging to IgG3 subclass might be involved in the pathogenesis of DCM, but further research is needed to elucidate this issue.
Autoimmune Dysregulation as a Possible Cause of Pregnancy-Related Cardiovascular Diseases
While most research has been focused on deciphering the cause versus consequence theories of AAb generation in the setting of DCM, the potential role of autoimmune dysregulation has also been extended to other at-risk clinical states. Recently, detection of AAbs in pregnancy-related cardiovascular diseases points to extension of this concept beyond dilated cardiomyopathy.
Peripartum Cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a serious disease during pregnancy with unknown etiology. Because of its rarity, the cause or pathology of the disease has not yet been fully investigated. A literature search only revealed a few published investigations which examined the correlation between autoimmunity and PPCM. However, the hypothesis of autoimmunity as a possible cause of PPCM is supported by the findings that AAbs against adenine nucleotide translocator, branched chain α-keto acid dehydrogenase, and cardiac myosin were found to be detected in patients with PPCM [75] . Furthermore, the serum titer of these three antibodies was observed to be higher in patients with versus without PPCM [75] . Whereas the IgG3 subclass antimyosin AAbs were predominant in DCM patients, AAbs detected in PPCM patients were subclass nonspecific. However, among these PPCM patients, the presence of AAbs belonging to IgG3 was still associated with higher New York Heart Association (NYHA) functional class and heart rate [76] . Although some potential correlation between IgG3-antimyosin AAbs and the pathology of PPCM would be suspected, this study was crosssectional in design and more longitudinal data will be needed to elucidate this issue. On the other hand, functionally active β 1 AR-AAb was detected in PPCM patients as well [77] . Recently, it was reported that β 1 AR-AAb and M 2 R-AAbs were detected in 60 and 46 % of PPCM patients, respectively. The frequency and titer of both β 1 AR-AAb and M 2 R-AAbs had a positive correlation with left ventricular dimension, plasma NT-proBNP level, and NYHA functional class and a negative correlation with LVEF. After 12 months, the titer and frequency of both AAbs significantly decreased [78] . Taken together, we can consider that the onset and course of PPCM accompanies some autoimmune activation, and it subsides in accordance with the amelioration of disease activity. However, further examination will be needed to elucidate the causal relationship between anticardiac AAbs and the pathology of PPCM.
Preeclampsia
Preeclampsia is characterized by proteinuria and hypertension during pregnancy. It is characterized by the presence of AAbs that bind to and activate the angiotensin II type 1 receptor (AT 1 R) [79] . AAbs against AT 1 R (AT 1 R-AAb) isolated from the sera of preeclamptic women increased reactive oxygen species (ROS) production, the NADPH oxidase components [80] , and intracellular Ca 2+ concentration in vitro [81] . Interestingly, the procedure of clipping ovarian arteries in pregnant rats to induce placental ischemia produced hypertension and proteinuria, representing the clinical features of preeclampsia [82] . A follow-up study found that AT 1 R-AAb was produced in this rat preeclampsia model [83] . AT 1 R-AAbs also were found to be detected in TNF-α-infused pregnant rats, while nonpregnant rats did not produce AT 1 R-AAbs [83] . Passive transfer of AT 1 R-AAb extracted from preeclampsia patients induced hypertension and proteinuria in pregnant mice, but not in nonpregnant ones [84] . Collectively, AT 1 RAAb works as one of the pathogenic factors in preeclampsia. However, the detailed mechanism by which AT 1 R-AAb is produced is still unknown.
Challenges in Clinical Translation
Despite these promising experimental findings, the applicability of AAbs testing and translation into clinical practice remains challenging. The first challenge is the issue of generalizability of findings and the lack of broad clinical availability of testing. AAbs are largely measured in single-center, crosssectional research studies (and often at a single-time point), in which autoimmune responses may differ among individuals or among geographic locations. In other words, their biological variability is largely unknown. The second challenge is the issue of availability and harmonization of laboratory assays. None of the AAb assays are clinically available; even measurements of AAbs against the same protein may vary widely, as they were developed by individual research laboratories without standardization. Finally, it has become increasingly clear that not all affected individuals have detectable AAbs. In addition, those with detectable AAbs may already have other established etiologies of heart failure, such as genetic/inherited or ischemic cardiomyopathies. It is therefore conceivable that pathogenic contributions of AAbs may only be applicable to a subset of susceptible individuals [24, 25, 85] . Whether targeting these subgroups may alter the natural history of the disease warrants further investigations.
Conclusions
AAbs can be produced in various diseases and conditions. Initially, it had been considered to act as a diagnostic marker for DCM of autoimmune origin. However, some of these AAbs are physiologically active and can function as causal factors in the pathogenesis of multiple cardiovascular diseases (including DCM, PPCM, and preeclampsia), particularly of the IgG3 subclass. Hence, detection of AAbs might identify those who have autoimmune origins that may warrant the early initiation of conventional antagonists against their pathogenic effects (e.g., β-blockers for β 1 AR-AAb). Promising novel therapies such as IA which removes AAbs or AAb-neutralizing agents are also under investigation, albeit only providing temporary relief through a more invasive mechanism. We believe these therapeutic tools targeting pathogenic AAbs can potentially benefit selected individuals suffering from their intractable conditions. Still, further examination is necessary in order to elucidate the roles of AAbs as a diagnostic tool in order to establish AAb-targeted personalized medicine for the population.
